[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].
At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented. The focus is on the clinical impact of these data. A group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data. The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC. Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m2 cabazitaxel.